Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
January 20, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
January 06, 2016 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments
December 10, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
--Peregrine and AstraZeneca Expand Immuno-Oncology Collaboration and Plan Phase II NSCLC Trial-- --Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
December 07, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015
December 03, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
November 09, 2015 08:05 ET
|
Peregrine Pharmaceuticals Inc.
- Bavituximab in Combination with Anti-PD-1 in Breast Cancer Studies Showed a Statistically Significant Improvement in Overall Survival as Compared to Subjects Receiving Anti-PD-1 Therapy Alone - -...
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
October 15, 2015 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2016 and Recent Developments
September 09, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
--Peregrine and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial-- --Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015-- ...
Peregrine Pharmaceuticals Declares Quarterly Dividend On Its Series E Convertible Preferred Stock
September 08, 2015 16:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 08, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
New Translational Data Highlights Bavituximab’s Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
September 08, 2015 08:05 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 08, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...